Drug intelligence / Profile preview

anti-CD22

Development stage: Preclinical
Lead developer: UDIBI
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

anti-CD22 is a monoclonal antibody currently in preclinical development by UDIBI-IPN (Unidad de Desarrollo e Investigación en Bioprocesos - Instituto Politécnico Nacional) for the treatment of cancer. The antibody specifically targets CD22 (B-lymphocyte antigen CD22), a transmembrane protein primarily expressed on the surface of mature B cells and overexpressed in various B-cell malignancies, including non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL). By binding to CD22, the antibody may trigger internalization or mediate immune-effector functions such as antibody-dependent cellular cytotoxicity (ADCC) to eliminate malignant B cells. As a target-specific therapeutic, it aims to provide a more selective treatment option for hematologic cancers.

Other names: Anti-CD22 monoclonal antibodyAnti-CD-22 monoclonal antibodyAnti-CD 22 monoclonal antibody

Targets

CD22 (Cluster of Differentiation 22)

Beyond the preview

Go deeper on anti-CD22.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-CD22.

Explore the full profile